Fireman B.V. (IFRX)

$0.95 -0.03 (-3.56%)
Market Cap 63.51M
Revenue (ttm) 180,000.00
Net Income (ttm) -49.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27,694.44%
Debt to Equity Ratio 0.00
Volume 339,200
Avg Vol 414,792
Day's Range N/A - N/A
Shares Out 67.13M
Stochastic %K 47%
Beta 1.48
Analysts Strong Sell
Price Target $10.29

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa,...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 3641 508 180
Address:
Winzerlaer Str. 2, Jena, Germany
cielo1
cielo1 Mar. 16 at 7:41 AM
$IFRX could we inch ever closer? Kindest regards to all!
0 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 15 at 3:23 PM
$IFRX sorry the link I posted didn't work. But it talks about how some researchers at the Krembil Brain Institute at the UHN believe that " complement proteins at the brain's borders may be key players" if Alzheimer's involves immune driven damage. They are investigating "where and how complement drives the disease. [in MS as well]These early studies will build scientific rationale for complement-targeting therapies to advance into human trials ." I reached out to a friend at the university who confirmed "there's definitely very active interest in the complement system in AD and neuroimmunology more broadly." Let's go IFRX. So many indications await.
0 · Reply
MrCompassion
MrCompassion Mar. 15 at 1:07 PM
$IFRX Pipeline in a product, into the future, continues, now of a kidney disease particularly suited to C5a signaling control. This of a market size comparable to AAV, the complement system proven causal to disease severity, proven a driver of the inflammatory cascade (no-brainer). The drug that accomplished that did what many others do: broke something in order to fix something else broken. That’s senseless healthcare, the kind that arrives with a boxed warning. INF904 is better than that, fixes what’s broken: common sense healthcare. A detailed read here, where I was very much a student as an author, made possible only by using an LLM such as Claude. IgAN is the disease, expect mentioned of it at CMD. Get ahead of the curve now. The biology of this disease demands C5a signaling intervention and it’ll get it, eventually. Hopefully sooner than later. https://nobrainerbio.substack.com/p/8-igan-the-young-kidney-claimed-by
0 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 14 at 1:09 PM
$IFRX https://globe2go.pressreader.com/@Reader24271730/csb_zo94HgGsq2kloC-_dYkf2FrqDT7C6ODZOMU-jxoTuJtagNiyKujUIUliHn4pxIhz9VJJ8UcRUR9eTAIsBCVVNw
1 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 14 at 1:06 PM
$IFRX The Globe and Mail (Ontario Edition) Mar 14, 2026 Page 71 Any suggestions on how to make medical researchers aware of our favourite little company ?
0 · Reply
MrCompassion
MrCompassion Mar. 14 at 6:17 AM
$IFRX More Claude-ChatGPT wizardry, part of a new project… Caption: “She is in her late twenties. She feels well. Her kidneys are still functioning. The biopsy confirmed what was already happening without her knowledge — immune complexes quietly depositing in the filtering tissue of her kidneys, complement activating, a self-amplifying inflammatory loop that her body cannot turn off on its own. The scarring has begun. Her nephrologist has left the room. The folder on the desk holds a diagnosis that will define the next twenty years of her life. Outside the window, the world continues. Inside, she is learning what it means to have a disease that arrived long before anyone thought to look for it. A story that is not sugar coated, involves an autoantibody, and a broken tap.”
1 · Reply
EdV3
EdV3 Mar. 13 at 10:31 PM
$IFRX ya'll scared of a delisting notice? Cmon lol
1 · Reply
trailblazerman9
trailblazerman9 Mar. 13 at 9:30 PM
$IFRX They received the NASDAQ deficiency notice March 11, 2026. The rules state they are required to inform shareholders immediately. Yet they sat on it 2 days and IR only shared the news at 5pm Eastern time Friday March 13.
1 · Reply
Buggenhout
Buggenhout Mar. 13 at 9:07 PM
$IFRX same shit InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Jena, Germany, March 13, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
0 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 13 at 9:06 PM
$IFRX so it's official. Deficiency notice has been PR'd.
0 · Reply
Latest News on IFRX
No data available.
cielo1
cielo1 Mar. 16 at 7:41 AM
$IFRX could we inch ever closer? Kindest regards to all!
0 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 15 at 3:23 PM
$IFRX sorry the link I posted didn't work. But it talks about how some researchers at the Krembil Brain Institute at the UHN believe that " complement proteins at the brain's borders may be key players" if Alzheimer's involves immune driven damage. They are investigating "where and how complement drives the disease. [in MS as well]These early studies will build scientific rationale for complement-targeting therapies to advance into human trials ." I reached out to a friend at the university who confirmed "there's definitely very active interest in the complement system in AD and neuroimmunology more broadly." Let's go IFRX. So many indications await.
0 · Reply
MrCompassion
MrCompassion Mar. 15 at 1:07 PM
$IFRX Pipeline in a product, into the future, continues, now of a kidney disease particularly suited to C5a signaling control. This of a market size comparable to AAV, the complement system proven causal to disease severity, proven a driver of the inflammatory cascade (no-brainer). The drug that accomplished that did what many others do: broke something in order to fix something else broken. That’s senseless healthcare, the kind that arrives with a boxed warning. INF904 is better than that, fixes what’s broken: common sense healthcare. A detailed read here, where I was very much a student as an author, made possible only by using an LLM such as Claude. IgAN is the disease, expect mentioned of it at CMD. Get ahead of the curve now. The biology of this disease demands C5a signaling intervention and it’ll get it, eventually. Hopefully sooner than later. https://nobrainerbio.substack.com/p/8-igan-the-young-kidney-claimed-by
0 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 14 at 1:09 PM
$IFRX https://globe2go.pressreader.com/@Reader24271730/csb_zo94HgGsq2kloC-_dYkf2FrqDT7C6ODZOMU-jxoTuJtagNiyKujUIUliHn4pxIhz9VJJ8UcRUR9eTAIsBCVVNw
1 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 14 at 1:06 PM
$IFRX The Globe and Mail (Ontario Edition) Mar 14, 2026 Page 71 Any suggestions on how to make medical researchers aware of our favourite little company ?
0 · Reply
MrCompassion
MrCompassion Mar. 14 at 6:17 AM
$IFRX More Claude-ChatGPT wizardry, part of a new project… Caption: “She is in her late twenties. She feels well. Her kidneys are still functioning. The biopsy confirmed what was already happening without her knowledge — immune complexes quietly depositing in the filtering tissue of her kidneys, complement activating, a self-amplifying inflammatory loop that her body cannot turn off on its own. The scarring has begun. Her nephrologist has left the room. The folder on the desk holds a diagnosis that will define the next twenty years of her life. Outside the window, the world continues. Inside, she is learning what it means to have a disease that arrived long before anyone thought to look for it. A story that is not sugar coated, involves an autoantibody, and a broken tap.”
1 · Reply
EdV3
EdV3 Mar. 13 at 10:31 PM
$IFRX ya'll scared of a delisting notice? Cmon lol
1 · Reply
trailblazerman9
trailblazerman9 Mar. 13 at 9:30 PM
$IFRX They received the NASDAQ deficiency notice March 11, 2026. The rules state they are required to inform shareholders immediately. Yet they sat on it 2 days and IR only shared the news at 5pm Eastern time Friday March 13.
1 · Reply
Buggenhout
Buggenhout Mar. 13 at 9:07 PM
$IFRX same shit InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Jena, Germany, March 13, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated March 11, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s ordinary shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).
0 · Reply
FelicitySmoak2
FelicitySmoak2 Mar. 13 at 9:06 PM
$IFRX so it's official. Deficiency notice has been PR'd.
0 · Reply
Yoyo35
Yoyo35 Mar. 13 at 9:06 PM
$IFRX finally 🫩 I’m actually glad the notice is out. It raises the pressure on management, and their next move will say a lot about strategy. If they still stay silent in the coming weeks on Phase 2b design and FDA feedback, then I’ll take that as a sign they’re waiting to bundle things into a bigger, denser package rather than releasing pieces one by one https://www.inflarx.de/Home/Investors/Press-Releases/Press-Release~2026-03-InflaRx-Announces-Receipt-of-Nasdaq-Deficiency-Notice-Regarding-Minimum-Bid-Price-Requirement-~.html
0 · Reply
EdV3
EdV3 Mar. 13 at 5:52 PM
$IFRX https://www.researchgate.net/publication/401754127_Defining_Moderate_Disease_and_Progression_in_Hidradenitis_Suppurativa_An_Expert_Framework_to_Unlock_the_Window_of_Opportunity_for_Prompt_Treatment
0 · Reply
MrCompassion
MrCompassion Mar. 13 at 5:20 PM
$IFRX I cleaned up the tap/mop article. Win-win for everyone to spread the word, more eyes, more dollars. Please share this link, help out InflaRx...and satisfy our own interests at the same time. https://nobrainerbio.substack.com/p/fix-the-tap-dont-mop-the-flood
0 · Reply
AngelInvestor_INF
AngelInvestor_INF Mar. 13 at 5:06 PM
$IFRX Nobody forgets that this company is valued at 66M$ while sitting on a compound which may bring 1Bn$ in peak revenue per year - or more. We just need to see more progress.
0 · Reply
Yoyo35
Yoyo35 Mar. 13 at 4:12 PM
$IFRX https://www.fiercepharma.com/pharma/jpm-2026-leo-pharma-hungry-more-partnerships-looks-widen-field-rare-dermatology-diseases Would LEO Pharma be a good deal partner candidate for InflaRx?
0 · Reply
trailblazerman9
trailblazerman9 Mar. 13 at 2:24 PM
$IFRX Finally.
0 · Reply
MrCompassion
MrCompassion Mar. 13 at 1:56 PM
$IFRX Anti-C5a good enough to walk on water...and then there's "JatK Vebifor" pretending to be JAK inhibitor: that guy better keep an eye out for ICE...immigration guns and in water ;) Here's v2. Share at will, a laugh worth a few billion. Take that Nasdaq! Happy Friday.
0 · Reply
FlowerInTheCellar
FlowerInTheCellar Mar. 13 at 10:18 AM
$IFRX https://zhuanlan.zhihu.com/p/2015822797113402625 -Camed Biological takes you on an exploration of C5AR1 (C5a receptor 1): from mechanism analysis to a new wind in drug research and development.- 13 March 2026 Please translate yourself. Mentions, including vilobelimab, are increasing 👍🏻
1 · Reply
MrCompassion
MrCompassion Mar. 13 at 5:36 AM
$IFRX Claude came up with the prompt, ChatGPT rendered
1 · Reply
EdV3
EdV3 Mar. 12 at 10:18 PM
$IFRX I love the setup here: - Quadruple bottom off that .80 level - Plenty of open up side gaps - No open downside gaps - Close above 50 MA - Poking above the weekly 5 EMA That's just off the charts. Fundamentals? Izi can drive massive value - they just need to execute.
1 · Reply
Yoyo35
Yoyo35 Mar. 12 at 8:36 PM
$IFRX What are people realistically hoping for on March 19? For me, the realistic menu is: • basic corporate update (so nothing 🫩) • clearer FDA / Phase 2b guidance for INF904 • maybe a Capital Markets Day date • anything more than that would probably be a bonus
3 · Reply
Yoyo35
Yoyo35 Mar. 12 at 4:08 PM
$IFRX I still find it a little odd to draw extra attention to what could be a potentially negative event. But at this stage, I don’t want to overinterpret every little signal or let my hopes get ahead of reality with InflaRx. I’m trying to stay more calm and grounded about it. Peace 🙏🏻🫩
4 · Reply